The company said sales for Q3 2025 were $800 million, up 8% from $740 million a year earlier on a reported basis and 8% in constant currency. Waters said its Pharmaceutical market grew 11% in constant currency.

1. 01

   The company said sales for Q3 2025 were $800 million, up 8% from $740 million a year earlier on a reported basis and 8% in constant currency. Waters said its Pharmaceutical market grew 11% in constant currency.

2. 02

   Waters said GAAP diluted earnings per share for Q3 were $2.50, below $2.71 a year earlier, while non-GAAP EPS was $3.40, up 16% from $2.93 a year earlier.

3. 03

   The company said that in adjusting from GAAP to non-GAAP diluted EPS for Q3, it reflected $0.47 in acquisition-related costs, $0.18 in financing costs and $0.15 in purchased intangibles amortization as per-share adjustments.

4. 04

   Waters said it is raising its 2025 constant currency sales growth guidance to +6.7% to +7.3% and its non-GAAP EPS guidance to $13.05 to $13.15. The company expects non-GAAP EPS for Q4 of $4.45 to $4.55.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.